XGX Pharma ApS: Financial statements 2022
CVR: 32289290
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 2,917,678 and a net result of DKK -1,842,554 compared with DKK 7,248,505 the year before. That is a decrease of 79.9% compared with the year before. Equity in the 2022 report amounted to DKK 13,798,737. The solvency ratio was 49.9%. The company had 4 employees in the financial year.
- Gross Profit
- DKK 2,917,678
- Profit/Loss
- DKK -1,842,554
- Equity
- DKK 13,798,737
- Total Assets
- DKK 27,639,683
- Employees
- 4
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 2.9 mio. | -1.8 mio. | 13.8 mio. | 4 |
| 2021 | - | 14.5 mio. | 7.2 mio. | 13.2 mio. | 3 |
| 2020 | - | 15.2 mio. | 6 mio. | 12.9 mio. | 3 |
| 2019 | - | 11.7 mio. | 8.4 mio. | 11.4 mio. | 3 |
| 2018 | - | 1.6 mio. | 27 t. | 59 t. | 1 |
Official annual report
Keep an eye on XGX Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
XGX Pharma ApS has published its annual report for 2021. Gross profit came to DKK 14,515,287, and the net result was DKK 7,248,505.
As of May 10, 2022, Mohammad Sohail Asghar has joined the board of directors of XGX Pharma ApS.
As of May 10, 2022, Rolf Eckersberg has left the board of directors of XGX Pharma ApS.
As of May 9, 2022, Mohammad Sohail Asghar has left the board of directors of XGX Pharma ApS.
About XGX Pharma ApS
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named VITAL PHARMA NORDIC ApS and VITAL PHARMA NORDIC HOLDING ApS. The management consists of Jens-Nikolaj Schøier. The board consists of Per Anders Larnholt (chair) and Johan Frödin. The company is owned by Unimedic Pharma AB. The company has 6 employees (2026). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.